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1,2-Didecanoylglycerol (diC,,) is taken up by human platelets and sequentially converted to 1,2-didecanoyl- 
phosphatidic acid (PA,,) and 1,2-didecanoylphosphatidylinositol (PI,,). Agents that increase cyclic AMP in 
platelets, such as prostacyclin and forskolin, sequentially convert diC,, to PAlo and PI,,,. They decrease for- 
mation of PA,, with a parallel accumulation of PI,,. This might reflect an inhibition of phosphatidylinositol 
kinase. 
Inositol phospholipid Phosphatidylinositol kinase Phosphatidic acid 
1. INTRODUCTION 
It has been observed that an increase of cyclic 
AMP in platelets decreases thrombin-induced for- 
mation of phosphatidic acid (this arises from 
phosphorylation of 1,2-diacylglycerol, which is 
produced by phosphodiesteratic leavage of the 
inositol phospholipids) and increases accumulation 
of phosphatidylinositol [1,2]. It was indicated that 
cyclic AMP does not inhibit phospholipase C 
(phosphodiesteratic cleavage of the inositol 
phospholipids) despite a profound reduction in the 
quantity of phosphatidate produced [ 11. It was 
hypothesized that cyclic AMP increases the con- 
version rate of phosphatidate to phosphatidylino- 
sitol, thereby decreasing the steady-state concen- 
tration of phosphatidate [1,2]. 
More recently it became apparent that phos- 
phatidylinositol bisphosphate is the preferential 
phospholipase C substrate for the formation of 
1,2-diacylglycerol and inositol trisphosphate, 
which are now considered as second messengers 
[3-61. During agonist-induced stimulation, ino- 
sitide kinases replenish phosphatidylinositol 
bisphosphate by sequential phosphorylations of 
phosphatidylinositol and phosphatidylinositol 
monophosphate [3,5]. Therefore, inhibition of 
phosphatidylinositol kinase by cyclic AMP 
decreases formation of phosphatidic acid and ac- 
cumulation of phosphatidylinositol [1,5]. In agree- 
ment with this, platelet-activating factor in the 
presence of cyclic AMP induces degradation of 
phosphatidylinositol bisphosphate and inhibits its 
subsequent resynthesis [7]. 
We have now used a synthetic 1,2-diacyl- 
glycerol, 1,2-didecanoylglycerol (diClo), that is 
metabolized by platelets to 1,2-didecanoylphos- 
phatidic acid (PAlo) and activates protein kinase C 
[8,9]. diClo is further converted to l,Zdidecanoyl- 
phosphatidylinositol (PIlo). Cyclic AMP decreases 
PAlo and increases PIlo similar to previous results 
with the endogenously produced phosphatidate 
and phosphatidylinositol [1,2]. 
2. EXPERIMENTAL 
2.1. Materials 
Carrier-free [32P]orthophosphate was obtained 
from New England Nuclear. myo-[2-3H]Inositol 
was from Amersham. diClo was from Serdary, On- 
tario. Precoated silica gel G-25 plates without gyp- 
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sum (layer thickness 0.25 mm) were from 
Macherey Nagel, Duren, FRG. Prostacyclin was 
from The Wellcome Research Laboratories, 
Beckenham, England. Forskolin was from 
Calbiochem-Behring. 
2.2. Preparation and labeling of human platelets 
with 32P or fH]inositol 
Blood (200 ml) was obtained from healthy 
human voluneers who had not received any 
medication in the previous 3 weeks. Blood was an- 
ticoagulated with 0.2 vol. ACD buffer (85 mM 
trisodium citrate, 111 mM dextrose and 71 mM 
citric acid, pH 5.5). Platelet-rich plasma was ob- 
tained by centrifugation at 200 x g for 20 min and 
was further centrifuged at 250 x g for 15 min. The 
platelet pellet obtained was resuspended in 10 ml 
of a modified Tyrode-Hepes buffer (134 mM 
NaCI, 12 mM NaHC03, 2.9 mM KCl, 0.36 mM 
NaHzP04, 1 mM MgC12, 5 mM glucose, 10 mM 
Hepes; pH 7.4) containing 5 ng/ml prostacyclin, 
and the platelets were incubated at 37°C for 
90 min with 2.5 mCi 32P. Platelets were washed 
twice with 30 ml of the modified Tyrode-Hepes 
buffer containing 5 ng/ml prostacyclin and 
resuspended in the same buffer without pros- 
tacyclin. Platelet concentration was adjusted to 8.0 
x lO*/ml using a Coulter Counter 2F (Coulter 
Electronic, USA). Samples (0.5 ml) were in- 
cubated at 37°C in a shaking incubator bath with 
10 PM diCre for various times as indicated in each 
experiment. Forskolin (0.1 mg/ml) or prostacyclin 
(0.1 pg/ml) were added to the platelets 2 min 
before diCro addition. 
2.3. Determination of phospholipids 
Reactions were stopped by addition of 1.88 ml 
chloroform/methanol/concentrated HCl (100: 
200 : 2, by vol.). Phases were separated by adding 
0.6 ml chloroform and 0.6 ml of 2 M KCl. The 
organic phase was dried under a flow of Nz and the 
inositides were separated on thin-layer plates (im- 
pregnated with 1% potassium oxalate containing 
2 mM EDTA) using chloroform, methanol and 
4 N NH40H (45 : 35 : 10, by vol.). The lipids were 
visualized by autoradiography [lo]. Experiments 
were run at least 5 times; each gave similar 
qualitative results. A representative xperiment in 
each case is presented. 
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3. RESULTS 
3.1. Formation of 1,2-didecanoylt2P]- 
phosphatidate and I,2-didecanoylp2Pj- 
phosphatidylinositol in human platelets 
prelabeled with 32P and exposed to 
exogenously added 1,2-didecanoylglycerol 
It has been shown that sn-1-oleoyl-Zacetyl- 
glycerol [l l] and 1,2-diCr0 [8] are converted to the 
corresponding [32P]phosphatidates in platelets 
prelabeled with 32P. These species of phospha- 
tidate are readily separated from [32P]phospha- 
tidate, which is produced in thrombin-stimulated 
platelets because of their fatty acid compositions. 
PhO - 
PI- 
P&l- 
PIP- 
- Ph 
- PI 
+ PA,, 
+ PIP 
TIME, min 
Fig. 1. Autoradiography of the formation of 1,2-dideca- 
noy1[32P]phosphatidic acid and 1,2-didecanoyl[32P]- 
phosphatidylinositol. Platelets prelabeled with 32P were 
exposed to 10 /IM 1,2-didecanoylglycerol for the in- 
dicated times. PIP2, phosphatidylinositol bisphosphate; 
PIP, phosphatidylinositol monophosphate; PAre, 
1,2-didecanoyl[32P]phosphatidic acid; PI, phosphatidyl- 
inositol; PIlo, 1,2-didecanoyl[32P]phosphatidylinositol. 
Unmarked radioactivity at the bottom indicates the 
origin and unmarked radioactivity near the solvent front 
corresponds to other platelet 32P-labeled phospholipids 
that were not individually resolved. 
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The endogenous species contain predominantly 
stearic acid in position 1 and arachidonic acid in 
position 2 [ 121. We used oxalate-impregnated thin- 
layer chromatographic plates [lo] to separate the 
endogenous [32P]inositol phospholipids from the 
1 ,2-didecanoyl[32P]phosphatidate and 1,2-dide- 
0 5 10 20 
TIME, min 
Fig.2. Effect of forskolin on the formation of 1,2-di- 
decanoyl[32P]phosphatidylinositol (PIlo) and 1,2-di- 
decanoyl[“P]phosphatidic acid (PAM). “P-labeled 
phospholipids were separated as in fig. 1. Other details as 
in fig.1. 
canoyl[32P]phosphatidylinositol (fig. 1). These 1,2- 
didecanoyl[32P]phospholipids were eluted and the 
phosphatidate further identified by separation in a 
previously reported chromatographic system [8]. 
The 1 ,2-didecanoyl[32P]phosphatidylinositol is
cleaved with phospholipase C (Clostridium wel- 
chill, and the [32P]inositol monophosphate is 
separated on Dowex 1 columns [5]. Maximal for- 
mation of [32P]PAio occurs at 5 min (figs 1 and 2). 
Thereafter, there is a gradual disappearance of 
[32P]PAie, with a concomitant increase in the for- 
mation of [32P]PIi0 (fig.2). 
3.2. Effect of prostacyclin and forskolin on 
1,2-didecanoylp2P]phosphatidate nd 
1,2-didecanoyif2P]phosphatidylinositol 
Prostacyclin and forskolin stimulate adenylate 
cyclase and increase the levels of cyclic AMP in 
platelets [ 13-151. This activates cyclic AMP- 
dependent protein kinases and phosphorylates 
specific proteins; this is most prominent with a 
50 kDa protein [16,17]. Cyclic AMP decreases the 
formation of the endogenous I-stearoyl-2-arachi- 
donylphosphatidate and increases the endogenous 
1 -stearoyl-2-arachidonylphosphatidylinositol in 
platelets that have been stimulated with thrombin 
[1,2]. Similarly, 0.1 pug/ml prostacyclin (not 
shown) or 0.1 mg/ml forskolin (fig.2) decrease the 
formation of PAio and increase accumulation of 
PIlo. These results are consistent with the 
hypothesis that an increase in platelet cyclic AMP 
might inhibit phosphatidylinositol kinase. 
4. DISCUSSION 
sn-1-Oleoyl-2-acetylglycerol - as well as several 
synthetic 1 ,Zdiacylglycerols with saturated acyl 
chains of 4, 6, 8 or 10 (diCi0) carbons - can be 
delivered into platelets and activate protein kinase 
C [8,9,11]. Under these conditions, 1,2-diacylglyc- 
erols are phosphorylated to the corresponding 
phosphatidic acid species by 1 ,Zdiacylglycerol 
kinase [8,11]. Chromatographic separations for 
1-oleoyl-2_acetylphosphatidate, 1,2-didecanoyl- 
phosphatidate and 1-decanoyllysophosphatidic 
acid have been reported [8,11,18]. In experiments 
that tested the effects of 1,Zdiacylglycerols on the 
metabolism of platelet inositides labeled with 32P 
[19], we recorded the formation of 2 new 32P- 
labeled products: [32P]PAio and [32P]PIi~ (fig. 1). 
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Exogenous 1 ,Zdiacylglycerols, with a fatty acid 
pattern different from the endogenously produced 
1,2-diacylglycerol, follow a similar metabolic 
pathway and can be differentiated chromatog- 
raphically; this provides an opportunity to study 
the regulation of the related enzymatic reactions. 
We have used the endogenous [32P]ATP pools to 
label the added, unlabeled 1 ,Zdiacylglycerol. The 
32P-labeled products of this 1,2-diacylglycerol are 
chromatographically separated from the endo- 
genous 32P radioactive phospholipids. In our pre- 
sent experiments, [32P]PIi~ is separated from 
[32P]PI; we have not been able to separate and 
identify the resultant products of further phos- 
phorylations of PIlo by inositide kinases. 
Our present information indicates that increases 
of platelet cyclic AMP affect the sequential con- 
version of diCio to PAio and PIi0 in a similar man- 
ner to the 1,Zdiacylglycerol that is endogenously 
produced in platelets stimulated with thrombin 
[1,2]. The similarity of the cyclic AMP effect in 
both cases suggests that phospholipase C is not af- 
fected, because the exogenously added 1,2-diacyl- 
glycerol bypasses the activation of phospholipase 
C. The accumulation of PIlo induced by cyclic 
AMP may reflect an inhibition of phosphatidyl- 
inositol kinase [5,7]. The inhibition of this kinase 
drastically reduces formation of polyphosphoino- 
sitides and the phospholipase C-induced formation 
of inositol trisphosphate and 1 ,Zdiacylglycerol [7] 
with concomitant accumulation of phosphatidyl- 
inositol [5]. The development of methods to 
separate diCio-derived polyphosphoinositides 
from the endogenous pecies will allow the study 
of this possibility and will provide a technique to 
test the effect of platelet agonists on the inositol 
phospholipids produced from synthetic 1,2-diacyl- 
glycerol added to platelets. 
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